New combo therapy aims to extend remission in ovarian cancer
NCT ID NCT06971744
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study tests whether adding two drugs, hydroxychloroquine and nelfinavir, to standard maintenance therapy can help keep high-grade serous ovarian cancer from coming back. About 38 women whose cancer responded well to initial platinum chemotherapy will receive the drug combination. The goal is to see if the treatment is safe and extends the time before the cancer progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.